Aesica's Queenborough site.
Aesica has appointed Adam Burgess to the position of product release manager. Adam’s wide ranging role includes managing the qualified persons (QP) team; directing and controlling QP activities in line with operational requirements. The role also involves the development of quality systems, product release, facilitating process improvements and acting as a QP.
Based at Queenborough, UK Adam has responsibility for pharmaceutical quality assurance (QA) across the Kent-based site. A key function is to ensure on time release of products. He will work closely with production personnel at the site, with the specific goal of ensuring that operational departments build quality into their processes and organisational structures. Adam reports directly to Christine Ernst, the site head of quality at Aesica, Queenborough, UK.
Previously, he held the position of manager, Defective Medicines Report Centre and import notification at the MHRA and was an active QP at Martindale Pharma. Prior to that, he worked as a QA Manager in preclinical quality assurance at GlaxoSmithKline. His expertise reaches across both commercial and clinical trial products including steriles, non-sterile tablets, capsules and liquids. Adam brings QA experience in laboratory, packaging and manufacturing area settings. He has strong skills in the risk assessment of pharmaceutical products and has authored position papers focused both on product quality and patient safety implications of unplanned events.
Remarking on his new position, Adam Burges said: “I am delighted to be appointed to this role at Aesica. It affords me the opportunity to return to pharmaceutical manufacturing and packaging, bringing the experience that I have gained at the UK regulator. This experience will help me to further enhance and drive quality culture initiatives across the company — in particular at Queenborough. I am looking forward to leading the product release team to ensure that all staff fully understand customer needs, consistently deliver results, whilst maintaining the high quality levels demanded and expected.”
Commenting on Adam Burgess’s appointment, Indira Walker, corporate quality director at Aesica remarked: “We are delighted that Adam has joined our QA team. He brings strong QA expertise and we are especially impressed by his combined experience of working both for prominent pharmaceutical companies and the MHRA regulatory authority.”
She continued: “We look forward to Adam contributing significantly to making further inroads into driving up QA standards so that we deliver the most consistent and best-in-class quality of service within the industry.”